Pancreatic Cancer
- References
1. Tsuchida H, Fujii T, Mizuma M, et al. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: a nationwide, cancer registry-based study from the Japan Pancreas Society. Surgery. 2019;166(6):997-1003.
2. Fukukura Y, Kumagae Y, Fujisaki Y, et al. Adding delayed phase images to dual-phase contrast-enhanced CT increases sensitivity for small pancreatic ductal adenocarcinoma. AJR Am J Roentgenol 2021;217(4):888-897.
3. Zins M, Matos C, Cassinotto C. Pancreatic adenocarcinoma staging in the era of preoperative chemotherapy and radiation therapy. Radiology. 2018;287(2):374-390.
4. Hong SB, Choi SH, Kim KW, et al. Meta-analysis of MRI for the diagnosis of liver metastasis in patients with pancreatic adenocarcinoma. J Magn Reson Imaging. 2019;51(6):1737-1744.
5. Wang L, Dong P, Wang WG, et al. Positron emission tomography modalities prevent futile radical resection of pancreatic cancer: a meta-analysis. Int J Surg. 2017;46:119-125.
6. Janick Selves, Elodie Long-Mira, Marie-Christine Mathieu, Philippe Rochaix, Marius Ilié, Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site, Cancers (Basel). 2018 Apr 5;10(4):108.
7. AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.
8. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology 2014;270:248-260.
9. Andreas Karachristos, Nikolaos Scarmeas, John P Hoffman, CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer, J Gastrointest Surg., 2005 Dec;9(9):1286-92.
10. Ghabi E, He J., Positive pancreatic neck margins-a telltale sign of complex biology. Hepatobiliary Surg Nutr. 2022 Apr;11(2):302-304.
11. Delpero JR, Bachellier P, Regenet N, et al. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford). 2014;16(1):20-33.
12. Delpero JR, Boher JM, Sauvanet A, et al. Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the association française de chirurgie. Ann Surg Oncol. 2015;22(6):1874-1883.
13. Mitchem JB, Hamilton N, Gao F, et al. Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure. J Am Coll Surg. 2012;214(1):46-52.
14. Tol JA, Gouma DJ, Bassi C, et al. Definition of a standard Lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156(3):591-600.
15. Farge D, Bournet B, Conroy T, et al. Primary thromboprophylaxis in pancreatic cancer patients: why clinical practice guidelines should be implemented. Cancers. 2020;12(3):618.
16. Schrag D, Uno H, Rosovsky R, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer:a randomized clinical trial. JAMA. 2023;329(22):1924-1933.
17. van der Gaag NA, Rauws EAJ, van Eijck CHJ, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362(2):129-137.
18. Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg.2018;105(8):946-958.
19. Cloyd JM, Heh V, Pawlik TM, et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020;9(4):1129.
20. Ghanem I, Lora D, Herradón N, et al. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials. ESMO Open. 2022;7(3):100485.
21. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473-1481.
22. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073-1081.
23. Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32(6):504-512.
24. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395-2406.
25. Conroy T, Castan F, Lopez A, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022;8(11):1571-1578.
26. Seufferlein T, Hammel P, Delpero JR, et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence.Cancer Treatment Rev. 2019;77:1-10.
27. Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9): 1263-1270.
28. Ye C, Sadula A, Ren S, et al. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. Cancer Chemother Pharmacol.2020;86(6):731-740.
29. Seufferlein T, Hammel P, Delpero JR, et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence. Cancer Treatment Rev. 2019;77:1-10.
30. Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801-810.
31. Van Laethem J-L. Induction chemotherapy in borderline (non-)resectable pancreatic cancer: a unique window of opportunity for understanding pancreatic cancer. Eur J Cancer. 2019;106:34-36.
32. Loos M, Kester T, Klaiber U, et al. Arterial resection in pancreatic cancer surgery: effective after a learning curve. Ann Surg. 2022;275(4):759-768.
33. Tee MC, Krajewski AC, Groeschl RT, et al. Indications and perioperative outcomes for pancreatectomy with arterial resection. J Am Coll Surg. 2018;227(2):255-269.
34. Lambert A, Schwarz L, Borbath I, et al. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol. 2019;11:175883591987556.
35. Halle-Smith JM, Hall L, Daamen LA, et al. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol. 2021;47(9):2248-2255.
36. Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423-2429.
37. Gill S, Ko Y-J, Cripps C, et al. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J ClinOncol. 2016;34(32):3914-3920.
38. Ohkawa S, Okusaka T, Isayama H, et al. Randomised phase II trial of S- 1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2015;112(9):1428-1434.
39. de la Fouchardiere C, Malka D, Chabaud S, et al. LBA60 Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: results of the randomized phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER study. Ann Oncol. 2022;33:S1426.